3 Business Services Stocks to Watch in a Prospering Industry
The Zacks Business Services industry is poised to prosper with rising demand and growing technology adoption. CTAS, APG and BFAM are three stocks that appear well-poised to ride this demand strength.
APi (APG) Is Up 13.03% in One Week: What You Should Know
Does APi (APG) have what it takes to be a top stock pick for momentum investors? Let's find out.
APi Group Corporation (APG) Q1 2025 Earnings Call Transcript
APi Group Corporation (NYSE:APG ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Adam Fee – Vice President of Investor Relations Russ Becker – President and Chief Executive Officer David Jackola – Executive Vice President and Chief Financial Officer Conference Call Participants Andy Kaplowitz – Citigroup Tim Mulrooney – William Blair Jasper Bibb – Truist Securities Andy Wittmann – Baird Kathryn Thompson – Thompson Research Group Stephanie Moore – Jefferies Steve Tusa – JPMorgan Josh Chan – UBS Jack Cauchi – Barclays Operator Good morning, ladies and gentlemen, and welcome to APi Group's First Quarter 2025 Financial Results Conference Call. All participants are now in a listen-only mode until the question-and-answer session.
APi (APG) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for APi (APG) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
APi (APG) Q1 Earnings and Revenues Beat Estimates
APi (APG) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.34 per share a year ago.
Apogee Therapeutics: Engineering Biologic Dominance
Apogee's strong financial position, with $731.1 million in cash, funds operations through Q1 2028, de-risking its ambitious pipeline development in inflammatory diseases. Significant R&D investments in lead IL-13 inhibitor APG777 and combination therapies reflect a strategic push for differentiated, best-in-class treatments in atopic dermatitis and asthma. Encouraging Phase 1 data for OX40L inhibitor APG990 supports its combination potential with APG777, promising infrequent dosing and broad efficacy in inflammatory diseases.
APi Group: Rating Downgrade As I Am Not Confident On FY25 Performance
I am downgrading APi Group (APG) to hold due to uncertain near-term performance, weak organic growth, and macro uncertainties impacting FY25 outlook. Despite solid 4Q24 adj EBITDA growth and a healthy backlog, APG's organic growth remains weak, particularly in the Specialty Services segment. APG's transition to high-margin ISM revenue is positive, but near-term organic growth concerns and potential macro risks could pressure the stock.
APi Group Corporation (APG) Q4 2024 Earnings Call Transcript
APi Group Corporation (NYSE:APG ) Q4 2024 Earnings Conference Call February 26, 2025 8:30 AM ET Company Participants Adam Fee - Vice President, Investor Relations Russell Becker - President and Chief Executive Officer David Jackola - Interim Chief Financial Officer Conference Call Participants David Paige - RBC Capital Markets Kathryn Thompson - Thompson Research Group Tim Mulrooney - William Blair Josh Chan - UBS Harold Antor - Jefferies Andy Wittmann - Baird Jon Tanwanteng - CJS Securities Operator Good morning, ladies and gentlemen, and welcome to APi Group's Fourth Quarter and Full-Year 2024 Financial Results Conference Call. All participants are in a listen-only mode until the question-and-answer session.
APi (APG) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for APi (APG) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
APi (APG) Q4 Earnings and Revenues Beat Estimates
APi (APG) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.44 per share a year ago.
APi Group: Expecting Growth To Accelerate And Adj EBITDA Margin To Expand
I reiterate a buy rating for APG due to strong market share potential, growth acceleration, and adj EBITDA margin expansion prospects for FY25 and beyond. APG's solid demand trend is evidenced by a $3.5 billion backlog, robust end markets, and a promising M&A pipeline, ensuring high-single-digit growth. Despite FY24 revenue guidance revision, project delays are temporary, setting up FY25 for stronger growth with positive proposal activity trends.
Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis
Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing and potential applications in asthma, COPD, and psoriasis. APGE's investigational pipeline includes APG808 and APG990, targeting different inflammatory pathways, enhancing its potential in the I&I market. APGE's strong cash runway and multiple upcoming catalysts, including Phase 2 results for APG777, justify its current valuation premium.
